India

Global Alliance for TB Drug Development (TB Alliance)

The partnership functions as a virtual R&D organization. By outsourcing medicine research and development projects, medicine compounds are moved along the development line to achieve regulatory approval and bring them to market at affordable prices for those countries experiencing the highest burden from TB.

GlaxoSmithKline: Nurse Training in Tamil Nadu

In the aftermath of the devastating Indian Ocean tsunami of 2004, GSK is providing USD 133,509 of funding from June 2007 to June 2009 to help Sri Ramakrishna Math, a local NGO in the Chennai region of Tamil Nadu, to enroll an additional 420 local girls in its Nursing Training Course. Sri Ramakrishna Math Chennai, in partnership with Direct Relief International, had already conducted extensive relief work in the area immediately after the tsunami, providing medicines, food, shelter and clothing.

GlaxoSmithKline's Sitamaquine for Leishmaniasis

Sitamaquine is GlaxoSmithKline's potential new once-a-day oral treatment for visceral leishmaniasis. This disease affects half a million people a year in the developing world and is usually fatal if untreated. Data from two Phase II proof-of-concept studies in Kenya and India are encouraging overall. After a 28-day course, 85% of patients remained cured at six months. Sitamaquine was generally well tolerated by patients in these studies. However, there were some concerns regarding renal adverse events seen in a few subjects, some of which appear to be treatment-related.

GlaxoSmithKline's PHASE Program

GlaxoSmithKline's Personal Hygiene & Sanitation Education (PHASE) project is helping to reduce diarrhea-related disease by encouraging school children to wash their hands. GSK established PHASE in 1998 and has so far invested over USD 7 million in the program. PHASE is run in partnership with AMREF, Save the Children and Earth Institute at Columbia University, as well as national Ministries of Health and Education in countries where the program is active. The program has had impressive results so far.

Ghazipur Children's Hospital

Pfizer Spain is supporting the Sabera Foundation, which runs a small Children's Hospital in Ghazipur, in the outskirts of Calcutta in India. The hospital provides specialized residential health care and rehabilitation services for the children of poor families. Pfizer helps fund maintenance of the building and the hospital's operating expenses infrastructures and makes available the company's expertise in health care. Therapeutic areas covered include physiotherapy, tuberculosis and ophthalmology. The hospital also provides out-patient support to the surrounding community.

Eurartesim International Development Program

Sigma-Tau S.p.A. and Medicines for Malaria Venture (MMV) have completed development of Eurartesim a fixed-dose Artemisinin-based Combination Therapy (ACT) which contains dihydroartemisinin (a derivative of artemisinin) and piperaquine. Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria. The registration dossier has been submitted to EMA on July 2009. The registration is expected during Q4 2010. After that, dossiers will be submitted to the endemic countries.

End Violence against Women and Prevent HIV and AIDS Program

Globally, violence against women is both a cause and a consequence of HIV/AIDS: women facing violence within intimate relationships often cannot negotiate safer sex practices, such as condom use. Rape and harmful practices such as female genital mutilation also spread the virus. In addition to untenable levels of stigma and discrimination from the community, women who test positive for HIV are often subjected to physical abuse from partners and can face eviction from their homes.

Bristol-Myers Squibb Foundation: Delivering Hope

'Delivering Hope' is a comprehensive effort to fight Hepatitis B and C in Asia, sponsored by the Bristol-Myers Squibb Foundation. Delivering Hope has drawn upon the proven models created by the Foundation's work on HIV/AIDS in Africa to address a major health care challenge in resource-constrained settings.

Bayer HealthCare & African Sleeping Sickness

In 2002, Bayer HealthCare agreed to supply - at no cost and for an initial five-year period - as much of the sleeping sickness medicine Germanin (suramin) as the World Health Organization (WHO) determines is needed to eliminate the disease. The initial donation comprised 50,000 ampoules. Bayer is also in favor of supporting an 'Integrated Sleeping Sickness Initiative' fostered by a broad base of institutions and covering all aspects of the disease from infection, diagnosis and therapy to prevention.

AstraZeneca Bangalore Research Institute

The AstraZeneca Bangalore Research Institute in India combines TB research and manufacturing capabilities.

Pages